AAAAAA

   
Results: 1-9 |
Results: 9

Authors: Sirulink, A Silver, RT Najfeld, V
Citation: A. Sirulink et al., Marked ploidy and BCR-ABL gene amplification in vivo in a patient treated with STI571, LEUKEMIA, 15(11), 2001, pp. 1795-1797

Authors: Cameron, CL Cella, D Herndon, JE Kornblith, AB Zuckerman, E Henderson, E Weiss, RB Cooper, MR Silver, RT Leone, L Canellos, GP Peterson, BA Holland, JC
Citation: Cl. Cameron et al., Persistent symptoms among survivors of Hodgkin's disease: An explanatory model based on classical conditioning, HEALTH PSYC, 20(1), 2001, pp. 71-75

Authors: Michiels, JJ Barbui, T Finazzi, G Fuchtman, SM Kutti, J Rain, JD Silver, RT Tefferi, A Thiele, J
Citation: Jj. Michiels et al., Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG, LEUK LYMPH, 36(3-4), 2000, pp. 239-253

Authors: Hensley, ML Peterson, B Silver, RT Larson, RA Schiffer, CA Szatrowski, TP
Citation: Ml. Hensley et al., Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: Analysis of cancer and leukemia Group B 9013, J CL ONCOL, 18(6), 2000, pp. 1301-1308

Authors: Engelhardt, M Mackenzie, K Drullinsky, P Silver, RT Moore, MAS
Citation: M. Engelhardt et al., Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture, CANCER RES, 60(3), 2000, pp. 610-617

Authors: Dewald, GW Wyatt, WA Silver, RT
Citation: Gw. Dewald et al., Atypical BCR and ABL D-FISH patterns in chronic myeloid leukemia and theirpossible role in therapy, LEUK LYMPH, 34(5-6), 1999, pp. 481

Authors: Michiels, JJ Kutti, J Stark, P Bazzan, M Gugliotta, L Marchioli, R Griesshammer, M van Genderen, PJJ Briere, J Kiladjian, JJ Barbui, T Finazzi, G Berlin, NI Pearson, TC Green, AC Fruchtmann, SM Silver, RT Hansmann, E Wehmeier, A Lengfelder, E Landolfi, R Kvasnicka, HM Hasselbalch, H Cervantes, F Reilly, JT Demory, JL Gisslinger, H Guardiola, P Martyre, MC Le Bousse-Kerdiles, MC Thiele, J
Citation: Jj. Michiels et al., Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis, NETH J MED, 54(2), 1999, pp. 46-62

Authors: Budd, GT Atiba, J Silver, RT Palmer, G Armstrong, S Otto, K Presant, C
Citation: Gt. Budd et al., Phase I/II trial of human recombinant granulocyte-colony-stimulating factor (filgrastim) and escalating doses of cyclophosphamide, mitoxantrone, and 5-FU in the treatment of advanced breast cancer, J CANC RES, 125(8-9), 1999, pp. 500-504

Authors: Silver, RT Woolf, SH Hehlmann, R Appelbaum, FR Anderson, J Bennett, C Goldman, JM Guilhot, F Kantarjian, HM Lichtin, AE Talpaz, M Tura, S
Citation: Rt. Silver et al., An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology, BLOOD, 94(5), 1999, pp. 1517-1536
Risultati: 1-9 |